Pharmacokinetic study of different doses of Depo Provera. Doses of DepoProvera of 25, 50, and mg were administered to four groups of women. The mean time for the return of follicular and luteal activity increased with increasing dose of DepoProvera.
Precautions Precautions Before taking medroxyprogesteronetell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. Some Canadian brands of this product may contain inactive ingredients such as soybeanwhich can cause allergic reactions or other problems.
Some people who are allergic to peanuts may also be allergic to soy. Talk to your pharmacist for more details.
This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: Before using this medication, tell your doctor or pharmacist your medical history, especially of: This drug may make you dizzy or drowsy.
Alcohol or marijuana can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Talk to your doctor if you are using marijuana.
You may need to stop the medication for a time or take special precautions because of the increased risk for blood clots. Ask your doctor for more details.
Smoking combined with this medication further increases your risk for strokes, blood clots, high blood pressureand heart attacks. This medication may cause blotchy, dark areas on your face and skin melasma. Sunlight may worsen this effect.
Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. This medication must not be used during pregnancy because it may harm an unborn baby, especially during the first 4 months of pregnancy. If you become pregnant or think you may be pregnant, inform your doctor right away.
This drug passes into breast milk.
Consult your doctor before breast-feeding.Do not take Provera (medroxyprogesterone tablets) if you are pregnant. This is not a list of all drugs or health problems that interact with Provera (medroxyprogesterone tablets).
Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. Depo-Provera is the brand name for a mg aqueous suspension of DMPA that is administered by intramuscular injection. The shot must be injected into thigh, buttock, or deltoid muscle four times a year (every 11 to 13 weeks), and provides pregnancy protection instantaneously after the first injection.
Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. DEPO-PROVERA should be used only if other treatments have been considered to be unsuitable or The World Health Organization Study, a component of a pooled analysis, showed an increased RR of (95% CI to ) of breast cancer associated with the use of DEPO-PROVERA in. Depo-Provera Sterile Aqueous Suspension contains medroxyprogesterone acetate, which is a derivative of progesterone and is active by the parenteral and oral routes of administration. It is a white to off-white, odorless crystalline powder, stable in air, melting between ° and ° C.
Medroxyprogesterone acetate (MPA), also known as depot medroxyprogesterone acetate (DMPA) and sold under the brand name Depo-Provera among others, is a hormonal medication of the progestin type.
  It is used as a method of birth control and as a part of menopausal hormone therapy. How to use Provera. Read the Patient Information Leaflet provided by your pharmacist before you start using this drug and each time you get a refill.
If you have any questions, consult your doctor. Pharmacokinetic study of different doses of Depo Provera. Fotherby K, Koetsawang S, Mathrubutham M. Doses of DepoProvera of 25, 50, and mg were administered to four groups of women. The mean time for the return of follicular and luteal activity increased with increasing dose of DepoProvera.
DEPO-PROVERA should be used only if other treatments have been considered to be unsuitable or The World Health Organization Study, a component of a pooled analysis, showed an increased RR of (95% CI to ) of breast cancer associated with the use of DEPO-PROVERA in.